1FOWLER S,GULSETH M P.Inpatient warfarin:experience with a pharmacistled anticoagulation management service in a tertiary care medical center[J].Am J Health Syst Pharm,2012,69(1):44-48.
9Taube J,Halsall D,Baqlin T.Influence of cytochrome P2450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over anticoagulation in patients on long2term treatment.Blood,2000,96(5):1816-1819
10Aithal G P,Day C P,Kesteven P J,et al.Association of polymorphisms in the cytochrome P450 CYP2C9 with wadarin dose requirement and risk of bleeding complications Lancet,1999,353(9154):717-719
1BUDNITZ D S, LOVEGROVE M C, SHEHAB N, et al. E- mergency hospitalizations for adverse drug events in older Americans[J]. N Engl J Med, 2011,365 (21) : 2002 - 2012.
2STONE N J, ROBINSON J, LICHTENSTEIN A H, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cho- lesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guide- lines [ J]. J Am Coll Cardiol,2013 :Epub ahead of print.
